-
Je něco špatně v tomto záznamu ?
Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements
A. Migliore, G. Gigliucci, L. Alekseeva, S. Avasthi, RR. Bannuru, X. Chevalier, T. Conrozier, S. Crimaldi, N. Damjanov, GC. de Campos, D. Diracoglu, G. Herrero-Beaumont, G. Iolascon, R. Ionescu, N. Isailovic, J. Jerosch, J. Lains, E. Maheu, S....
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2019
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-10-01
Nursing & Allied Health Database (ProQuest)
od 2009-10-01
Health & Medicine (ProQuest)
od 2009-10-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
31903099
DOI
10.1177/1759720x19893800
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Background: In this work, we aimed to establish a clinical target in the management of knee osteoarthritis (KOA) and to propose good clinical practice (GCP) statements for carrying out a treat-to-target strategy. Methods: A steering committee of seven experts had formulated a provisional set of recommendations that were exposed for discussion and modification to a technical expert panel (TEP) of 25 multidisciplinary experts from Europe, North America, South America and Asia. The level of evidence and strength of each recommendation was discussed. The TEP formulated overarching principles and GCP statements based on the level of agreement for each item with a vote using a 10-point numerical scale. Results: Two overarching principles and 10 GCP statements were formulated by the TEP. These GCP statements suggest: treatment should achieve clinical improvement bringing the patient to the Patient Acceptable Symptom State (PASS); pharmacological and nonpharmacological treatment should begin as early as possible, with an early diagnosis of symptomatic KOA; the patient should be evaluated every 3-6 months; risk factors of KOA progression should be identified and managed with patients at the beginning of the treatment and monitored regularly; treatment should be adapted according to patient phenotype and disease severity; healthy lifestyle must be promoted and monitored. The level of agreement average ranged from 8.7 to 9.6 on scale. Conclusions: The proposed overarching principles and GCP statements have the aim of involving patients, general practitioners and multidisciplinary specialists in sharing a therapeutic treat-to-target strategy for KOA management based on the best evidence and expert opinions.
2nd Rehabilitation Department Rehabilitation Clinical Hospital Cluj Napoca Romania
Chirurgia Ortopedica Mininvasiva e Nuove Tecnologie Humanitas Research Hospital Castellanza Italy
Department of Emergency Medicine Dr Ram Manohar Lohia Hospital Lucknow India
Department of Experimental and Clinical Medicine University of Florence Florence Italy
Department of Family Medicine School of Kinesiology University Western Ontario Ontario Canada
Department of Orthopaedics and Traumatology 'Policlinico Tor Vergata' Foundation Rome Italy
Department of Orthopaedics and Traumatology University of Campinas São Paulo Brazil
Department of Rheumatology Belorussian State Medical University Minsk Belarus
EUPATI Graduate and Patient Advocate Brussels Belgium
Institute of Rheumatology Prague Czech Republic
Institute of Rheumatology University of Belgrade Medical School Belgrade Serbia
Joint and Bone Research Unit IIS Fundacion Jimenez Diaz UAM Madrid Spain
Orthopaedic Department Johanna Etienne Hospital Neuss Germany
Rheumatology Department AP HP Saint Antoine Hospital Paris France
Rheumatology Unit San Pietro Fatebenefratelli Hospital Rome Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20005432
- 003
- CZ-PrNML
- 005
- 20200604160219.0
- 007
- ta
- 008
- 200511s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/1759720X19893800 $2 doi
- 035 __
- $a (PubMed)31903099
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Migliore, Alberto $u Rheumatology Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy.
- 245 10
- $a Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements / $c A. Migliore, G. Gigliucci, L. Alekseeva, S. Avasthi, RR. Bannuru, X. Chevalier, T. Conrozier, S. Crimaldi, N. Damjanov, GC. de Campos, D. Diracoglu, G. Herrero-Beaumont, G. Iolascon, R. Ionescu, N. Isailovic, J. Jerosch, J. Lains, E. Maheu, S. Makri, N. Martusevich, M. Matucci Cerinc, M. Micu, K. Pavelka, RJ. Petrella, U. Tarantino, R. Raman,
- 520 9_
- $a Background: In this work, we aimed to establish a clinical target in the management of knee osteoarthritis (KOA) and to propose good clinical practice (GCP) statements for carrying out a treat-to-target strategy. Methods: A steering committee of seven experts had formulated a provisional set of recommendations that were exposed for discussion and modification to a technical expert panel (TEP) of 25 multidisciplinary experts from Europe, North America, South America and Asia. The level of evidence and strength of each recommendation was discussed. The TEP formulated overarching principles and GCP statements based on the level of agreement for each item with a vote using a 10-point numerical scale. Results: Two overarching principles and 10 GCP statements were formulated by the TEP. These GCP statements suggest: treatment should achieve clinical improvement bringing the patient to the Patient Acceptable Symptom State (PASS); pharmacological and nonpharmacological treatment should begin as early as possible, with an early diagnosis of symptomatic KOA; the patient should be evaluated every 3-6 months; risk factors of KOA progression should be identified and managed with patients at the beginning of the treatment and monitored regularly; treatment should be adapted according to patient phenotype and disease severity; healthy lifestyle must be promoted and monitored. The level of agreement average ranged from 8.7 to 9.6 on scale. Conclusions: The proposed overarching principles and GCP statements have the aim of involving patients, general practitioners and multidisciplinary specialists in sharing a therapeutic treat-to-target strategy for KOA management based on the best evidence and expert opinions.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gigliucci, Gianfranco $u Rheumatology Unit, San Pietro Fatebenefratelli Hospital, Rome, Italy.
- 700 1_
- $a Alekseeva, Liudmila $u Department of Metabolic Diseases of Bone and Joints, VA Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
- 700 1_
- $a Avasthi, Sachin $u Department of Emergency Medicine, Dr Ram Manohar Lohia Hospital, Lucknow, India.
- 700 1_
- $a Bannuru, Raveendhara R $u Centre for Treatment Comparison and Integrative Analysis Division of Rheumatology, Tufts Medical Centre, Boston, MA, USA.
- 700 1_
- $a Chevalier, Xavier $u Unit of Rheumatology, Henri Mondor Hospital, Créteil, France.
- 700 1_
- $a Conrozier, Thierry $u Service de Rhumatologie, Hôpital Nord Franche, Belfort, France.
- 700 1_
- $a Crimaldi, Sergio $u Chirurgia Ortopedica Mininvasiva e Nuove Tecnologie, Humanitas Research Hospital, Castellanza, Italy.
- 700 1_
- $a Damjanov, Nemanja $u Institute of Rheumatology, University of Belgrade Medical School, Belgrade, Serbia.
- 700 1_
- $a de Campos, Gustavo Constantino $u Department of Orthopaedics and Traumatology, University of Campinas, São Paulo, Brazil.
- 700 1_
- $a Diracoglu, Demirhan $u Department of Physical Medicine and Rehabilitation Division of Pain Medicine, Istanbul University, Istanbul, Turkey.
- 700 1_
- $a Herrero-Beaumont, Gabriel $u Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.
- 700 1_
- $a Iolascon, Giovanni $u Department of Medical and Surgical Specialties and Dentistry, University of Campania 'L Vanvitelli', Caserta, Italy.
- 700 1_
- $a Ionescu, Ruxandra $u Department of Internal Medicine and Rheumatology Sf. Maria Hospital, University of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania.
- 700 1_
- $a Isailovic, Natasa $u Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Via A. Manzoni 56, Rozzano, Milan 20089, Italy.
- 700 1_
- $a Jerosch, Jörg $u Orthopaedic Department, Johanna Etienne Hospital, Neuss, Germany.
- 700 1_
- $a Lains, Jorge $u Physical Rehabilitation Medicine Department, Rovisco Pais Medical and Rehabilitation Centre, Tocha, Portugal.
- 700 1_
- $a Maheu, Emmanuel $u Rheumatology Department, AP-HP, Saint-Antoine Hospital, Paris, France.
- 700 1_
- $a Makri, Souzi $u EUPATI Graduate and Patient Advocate, Brussels, Belgium.
- 700 1_
- $a Martusevich, Natalia $u Department of Rheumatology, Belorussian State Medical University, Minsk, Belarus.
- 700 1_
- $a Matucci Cerinc, Marco $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
- 700 1_
- $a Micu, Mihaela $u Second Rehabilitation Department, Rehabilitation Clinical Hospital, Cluj-Napoca, Romania.
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology, Prague, Czech Republic.
- 700 1_
- $a Petrella, Robert J $u Department of Family Medicine, School of Kinesiology University Western Ontario, Ontario, Canada.
- 700 1_
- $a Tarantino, Umberto $u Department of Orthopaedics and Traumatology, 'Policlinico Tor Vergata' Foundation, Rome, Italy.
- 700 1_
- $a Raman, Raghu $u Academic Department of Orthopaedics, Hull and East Yorkshire NHS Trust Castle Hill Hospital, Cottingham, UK.
- 773 0_
- $w MED00203334 $t Therapeutic advances in musculoskeletal disease $x 1759-720X $g Roč. 11, č. - (2019), s. 1759720X19893800
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31903099 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200604160217 $b ABA008
- 999 __
- $a ind $b bmc $g 1524362 $s 1095487
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 11 $c - $d 1759720X19893800 $e 20191219 $i 1759-720X $m Therapeutic advances in musculoskeletal disease $n Ther Adv Musculoskelet Dis $x MED00203334
- LZP __
- $a Pubmed-20200511
